Enter Note Done
Go to previous page in this tab
Session
  • Presentation | Gaining CONFIDENCE: Using Finerenone and SGLT2i to Optimize Cardiac and Kidney Outcomes
  • Population
  • Share Icon
    Map Icon
    Bookmark Icon
  • Finerenone and Real-World Hyperkalemia Rates in Individuals with Triple Comorbidities-Heart Failure, Chronic Kidney Disease, and Type 2 Diabetes
    • Schedule
    Notes
  • MDP1990
    Set Timezone
    •  
    View Map

Generic 'disconnected' Message
ALANNA A MORRIS, Bayer Pharmaceuticals, Atlanta, GA; Janani Rangaswami, George Washington Univ, Falls Church, VA; Matthew R Weir, Univ Maryland Sch Med, Lutherville, MD; Yunxun Wang, Bayer, Livingston, NJ; Mauricio Beller Ferri, Bayer Pharmaceuticals, Skillman, NJ; Arvind Katta, Bayer US Pharmaceuticals, LLC, Whipanny, NJ; Jacob Earl, Carolina Aldworth, Bayer US Pharmaceuticals LLC, Whippany, NJ; Gianni Amato, Bayer US Pharmaceuticals LLC, Whipanny, NJ; Zihe Zheng, Bayer US Pharmaceuticals LLC, West Windsor, NJ
Communities
Navigation
Session Type
Onsite Viewing
Main Session